School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur, 495009 (C.G.) India.
Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Bhilai, 490020, India.
Anticancer Agents Med Chem. 2024;24(4):288-303. doi: 10.2174/0118715206265278231026101739.
In current scenario breast cancer measured as one of the dangerous health issues. An effective therapeutic class of drug known as aromatase inhibitors (AIs) is dominant against estrogen receptorpositive breast cancer. However, there is an urgent need to create target-specific AIs with better anti-breast cancer profiles due to the increased toxicity and adverse effects related to currently existing anti-breast cancer drugs.
In the present study, we have designed of 100 novel tiazole analogues as aromatase inhibitors their pharmacophoric features were explored.
Molecular docking was applied to a series of 4-substituted-1, 2, 3-triazoles containing letrozole for their aromatase inhibitory effects. The aromatase inhibitory activity of the compound in a series varies in the range of (IC = 0.008-31.26 μM). A hydrogen atom positioned at R1 of the triazole ring in compound (01) was responsible for the most potent compound (IC = 0.008 μM) in the series of 28 compounds as compared to letrozole. The self-organizing molecular field study was used to assess the molecular characteristics and biological activities of the compounds. The four models were developed using PLS and MLR methods. The PLS method was good for statistical analysis. The letrozole scaffold-based 100 compounds were designed by selecting an effective pharmacophore responsible for aromatase inhibitory activity. The designed compound was placed on the previous model as a test set, and its IC values were calculated.
Hydrogen bonds were established between the potent molecule (01) and the essential residues Met 374 and Arg 115, which were responsible for the aromatase-inhibiting action. Cross-validated q2 (0.6349) & noncross- validated r2 (0.7163) were discovered in the statistical findings as having reliable predictive power. Among 100 designed compounds, seven compounds showed good aromatase inhibitory activities.
The additional final SOMFA model created for the interactions between the aromatase and the triazole inhibitors may be helpful for future modification and enhancement of the inhibitors of this crucial enzyme.
在当前情况下,乳腺癌被视为一种危险的健康问题。一种有效的治疗药物,即芳香酶抑制剂(AIs),对雌激素受体阳性乳腺癌具有显著疗效。然而,由于目前存在的抗乳腺癌药物毒性和不良反应增加,迫切需要开发具有更好的抗乳腺癌特性的靶向特异性 AIs。
在本研究中,我们设计了 100 种新型噻唑类化合物作为芳香酶抑制剂,并探讨了它们的药效特征。
应用分子对接研究了一系列含有来曲唑的 4-取代-1,2,3-三唑类化合物的芳香酶抑制作用。该系列化合物的芳香酶抑制活性在 0.008-31.26 μM 范围内变化。与来曲唑相比,在 28 个化合物系列中,化合物(01)中噻唑环 R1 上的一个氢原子使最有效的化合物(IC=0.008 μM)。自组织分子场研究用于评估化合物的分子特征和生物活性。使用 PLS 和 MLR 方法开发了四个模型。PLS 方法适用于统计分析。基于来曲唑支架的 100 个化合物通过选择负责芳香酶抑制活性的有效药效团进行设计。将设计的化合物置于以前的模型中作为测试集,并计算其 IC 值。
与必需残基 Met 374 和 Arg 115 建立氢键的强分子(01),负责芳香酶抑制作用。统计发现,交叉验证 q2(0.6349)和非交叉验证 r2(0.7163)具有可靠的预测能力。在 100 个设计的化合物中,有 7 个化合物表现出良好的芳香酶抑制活性。
为芳香酶和三唑抑制剂之间的相互作用创建的附加最终 SOMFA 模型可能有助于对这种关键酶抑制剂的进一步修饰和增强。